ABBOTT PARK, Ill., Nov. 10, 2021 — Abbott today released new global market research from its Beyond Intervention initiative, the company’s multi-year global research program designed to examine the vascular patient experience from the perspectives of patients, physicians and healthcare leaders. The latest research focuses on challenges that arise for physicians and patients during the earliest stages of the patient journey, uncovering new opportunities for health systems and hospitals to leverage technology, break down existing barriers and improve patient care.
The findings from Beyond Intervention identify several key areas for improvement related to the diagnosis and treatment of cardiovascular disease. These include reducing inconsistencies in patient care delivery, improving access to technology to support accurate diagnosis, and addressing issues of health equity that result in inadequate care for underserved communities. The report also underscores the differences in how patients and healthcare providers perceive the effectiveness of the care being delivered.
"The latest data from the Beyond Intervention initiative reveals diverging views between patients and healthcare administrators on how each views the patient experience and the impact of inequities across the healthcare continuum," said Nick West M.D., chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business. "This research solidifies the need for physicians to leverage innovative technologies to improve the ability to make and communicate a diagnosis as early as possible in the patient journey."
Key Research Findings
The Beyond Intervention initiative secured feedback from more than 1,800 patients with cardiovascular disease, physicians and healthcare leaders. The research uncovered the growing demand for an industry-wide standard in technology to better assess vascular diseases. Insights from this research can help hospitals and physicians improve the patient experience.
Key insights from the research include:
"Inherent biases can hinder a physician’s ability to detect and recognize symptoms, especially for populations that have been historically misdiagnosed in the cardiovascular disease setting; such as young, female and certain ethnicities," said Natalia Pinilla-Echeverri, M.D., assistant professor of medicine at McMaster University in Ontario, Canada, and interventional cardiologist at Hamilton Health Sciences/Niagara Health. "Research efforts must be developed on innovative technologies that can support physicians, like screening and stratification tools that can minimize the physician’s individual perspective and biases in order to improve long-term patient outcomes."
Creating Diversity in Treatments to Serve Every Community
Abbott is committed to addressing barriers to healthcare, especially for those from underserved communities. The company is currently developing a new therapy to treat PAD, which is now being tested in a clinical trial. Abbott’s Life-BTK trial demonstrates its commitment to recruiting diverse participants to treat PAD. Too often, clinical trials are not representative of communities, especially those that are significantly or disproportionately affected by a disease state. By focusing on diversity and inclusion, Abbott is working to address health inequities and ensure products meet the needs of patients who need them the most.
PAD is a chronic circulatory condition that reduces blood flow to the legs, which, if left untreated, can result in unnecessary limb amputations and sometimes death. An estimated 200 million people have been diagnosed with PAD worldwide[i], which disproportionately affects people of color. The Beyond Intervention research showcases that patients with PAD perceive they have a consistently more challenging experience, see more doctors, and are more likely to receive ineffective treatment than patients with CAD.
About Beyond Intervention Research:
Abbott surveyed 1,800 stakeholders, including 1,289 vascular disease patients, 408 healthcare physicians and 173 healthcare leaders from April to June 2021. Respondents to the online survey represent 13 countries: Australia, Brazil, Canada, China, Germany, India, Italy, Japan, New Zealand, Saudi Arabia, Spain, United Kingdom and United States.
The Beyond Intervention global market research uncovers the challenges that arise within the earliest stages of the patient journey, and focuses on several key issues, including improving care and supporting underserved communities; it also underscores the different perspectives between patients and healthcare leaders on care and the patient experience. The study is a follow-up to last year’s "Personalized Vascular Care Through Technological Innovation" worldwide research, which emphasized patients’ desire for a personalized, "tailored for me" healthcare experience across the care continuum.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.